# Safety and Efficacy Study of RVL-1201 in Acquired Blepharoptosis

> **NCT01848041** · PHASE1,PHASE2 · COMPLETED · sponsor: **RVL Pharmaceuticals, Inc.** · enrollment: 46 (actual)

## Conditions studied

- Blepharoptosis

## Interventions

- **DRUG:** RVL-1201
- **DRUG:** RVL-1201 Vehicle Placebo

## Key facts

- **NCT ID:** NCT01848041
- **Lead sponsor:** RVL Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-05
- **Primary completion:** 2014-01
- **Final completion:** 2014-02
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2021-11-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01848041

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01848041, "Safety and Efficacy Study of RVL-1201 in Acquired Blepharoptosis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01848041. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*